G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
18 oct. 2023 07h30 HE
|
G1 Therapeutics
G1 Therapeutics to release 3Q23 financial results on November 1, 2023
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
16 oct. 2023 09h00 HE
|
G1 Therapeutics
G1 to present four posters at the 2023 ASCO Quality Care Symposium
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 11h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 sept. 2023 16h15 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
02 août 2023 06h30 HE
|
G1 Therapeutics
- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3...
G1 Therapeutics to Participate in Two August Investor Conferences
31 juil. 2023 14h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August...
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
31 juil. 2023 08h30 HE
|
G1 Therapeutics
- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed...
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
26 juil. 2023 09h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2023 16h15 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 06, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
04 juin 2023 07h13 HE
|
G1 Therapeutics
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - - Trilaciclib Enhances Expression of Genes Associated with Memory T...